Therapeutic Endpoint in Pediatric IBD Conditions
- Conditions
- Colitis, UlcerativeInflammatory Bowel DiseasesCrohn Disease
- Interventions
- Other: AlgometRx Nociometer
- Registration Number
- NCT06065228
- Lead Sponsor
- Children's National Research Institute
- Brief Summary
The purpose of this clinical study is the development of physiologic endpoint of inflammation in pediatric patients diagnosed with inflammatory bowel disease (IBD), specifically subtypes Crohn's disease (CD) and ulcerative colitis (UC). The novel medical device evaluates the patient's sensory response to each of the three sensory nerve fiber types. Data from the device provides an assessment of disease activity and a more precise approach to treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 60
- Male or female ≥ 6 years of age at screening.
- Documentation of an IBD diagnosis as evidenced by history
- Documented history of eye disease precluding pupillometry
- Patients who are unwilling or unable to participate due to developmental delays or ongoing psychological diagnoses.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description UC AlgometRx Nociometer - CD AlgometRx Nociometer -
- Primary Outcome Measures
Name Time Method The primary objective of this study is the measurement of the nociceptive index for clinical output. 1 Year
- Secondary Outcome Measures
Name Time Method The secondary objective of this study is the characterization of the nociceptive index in IBD populations in response to standard of care interventions. 1 Year
Trial Locations
- Locations (1)
Children's National Health System
🇺🇸Washington, District of Columbia, United States